Trial Parameters
Brief Summary
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Eligibility Criteria
Inclusion Criteria: 1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or 2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute; 3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment; 4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient; 5. A confirmed diagnosis of cancer based on medical oncology medical records. Exclusion Criteria: 1. Patients not diagnosed with cancer; 2. Telehealth patients; 3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires; 4. Unwilling to participate in the AIMS Institute observational study.